Skip to main content

Market Overview

UPDATE: Bank of America Downgrades Salix Pharmaceuticals, Keeps PO


In a report published Tuesday, Bank of America Merrill Lynch analyst Gregg Gilbert downgraded Salix Pharmaceuticals (NASDAQ: SLXP) to Underperform from Neutral, keeping its $86.00 price objective.

According to the report, SLXP's base business has been performing well, led by continued solix Xifaxan growth for hepatic encephalopathy and strong share gains for Apriso following a disruptive competitor launch in the ulcerative colitis market. The analysts believe continued strong growth for both will be necessary to support the stock.

“SLXP was one of the better performing stocks in 2013 within our Specialty Pharma coverage group with a 122% return,” the report said. “Over the last few months, we've raised our PO to reflect stronger performance for the base business, more credit for the late-stage pipeline, and significant contribution from the Santarus acquisition (announced on 11/7). With the stock now trading above our PO, which we believe reflects a relatively bullish set of assumptions, we are moving to an Underperform rating.”

SLXP closed Monday at $90.43.

Latest Ratings for SLXP

Mar 2015JefferiesDowngradesBuyHold
Feb 2015Cantor FitzgeraldDowngradesBuyHold
Feb 2015UBSDowngradesBuyNeutral

View More Analyst Ratings for SLXP
View the Latest Analyst Ratings


Related Articles (SLXP)

View Comments and Join the Discussion!

Posted-In: Bank of America Merrill Lynch Gregg GilbertAnalyst Color Downgrades Analyst Ratings

Latest Ratings

KRYSHC Wainwright & Co.Maintains103.0
OTRKRBC CapitalDowngrades32.0
EVHCanaccord GenuityMaintains24.0
BMRNCanaccord GenuityMaintains91.0
ONTFCanaccord GenuityInitiates Coverage On65.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at